<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647526</url>
  </required_header>
  <id_info>
    <org_study_id>PBP-301</org_study_id>
    <nct_id>NCT04647526</nct_id>
  </id_info>
  <brief_title>Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment</brief_title>
  <acronym>SPLASH</acronym>
  <official_title>A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POINT Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POINT Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in&#xD;
      patients with metastatic castration-resistant prostate cancer who have progressed following&#xD;
      treatment with androgen receptor axis-targeted therapy (ARAT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine the efficacy of [Lu-177]-PNT2002&#xD;
      ([Lu-177]-PSMA-I&amp;T) versus abiraterone or enzalutamide in delaying radiographic progression&#xD;
      in patients with mCRPC.&#xD;
&#xD;
      The study consists of 3 phases: Dosimetry, Randomized Treatment, and Long term Follow up.&#xD;
&#xD;
      The study will commence with a 25-patient safety and dosimetry lead-in (Part 1) and proceed&#xD;
      to a randomization treatment phase in approximately 390 patients (Part 2). Patients in Part 2&#xD;
      will be randomized in a 2:1 ratio to receive either [Lu-177]-PNT2002 (Arm A), or enzalutamide&#xD;
      or abiraterone (Arm B). Patients in Arm B who experience radiographic progression per central&#xD;
      review and meet protocol defined eligibility, may crossover to receive [Lu-177]-PNT2002. All&#xD;
      patients will be followed in long-term follow-up for at least 5 years from the first&#xD;
      therapeutic dose, death, or loss to follow up (Part 3).&#xD;
&#xD;
      Only patients that meet PSMA PET avidity criteria per central review will be eligible for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Progression Free Survival (rPFS)</measure>
    <time_frame>32 weeks</time_frame>
    <description>Time in months from the date of randomization to radiological progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) or confirmed progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3) (bone), or death from any cause, as assessed by blinded independent central review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>32 weeks</time_frame>
    <description>Proportion of patients with partial or complete response (PR or CR, respectively) by BICR based on RECIST 1.1 criteria (soft tissue) and PCWG3 criteria (bone).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>32 weeks</time_frame>
    <description>Time from the first date of CR or PR by BICR to the first occurrence of radiographic progression (PD) by BICR based on PCWG3 modified RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from the date of randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response</measure>
    <time_frame>32 weeks</time_frame>
    <description>Proportion of patients achieving a ≥50% decrease in PSA (PCWG3 criteria) from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Progression-Free Survival (bPFS)</measure>
    <time_frame>32 weeks</time_frame>
    <description>Time from randomization to the date of the first PSA increase from baseline ≥25% and ≥2 ng/mL above nadir confirmed by a second PSA measurement defining progression ≥3 weeks later, as per PCWG3.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability (AEs)</measure>
    <time_frame>5 years</time_frame>
    <description>Frequency and severity of AEs, graded and categorized using CTCAE v. 5.0.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">415</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>[Lu-177]-PNT2002 (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[Lu-177]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm (Arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[Lu-177]-PNT2002</intervention_name>
    <description>Participants randomized to Arm A will receive 6.8 GBq (±10%) of [Lu-177]-PNT2002 every 8 weeks for 4 cycles</description>
    <arm_group_label>[Lu-177]-PNT2002 (Arm A)</arm_group_label>
    <other_name>[Lu-177]-PSMA-I&amp;T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone)</description>
    <arm_group_label>Control Arm (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide (160 mg orally qd)</description>
    <arm_group_label>Control Arm (Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male aged 18 years or older.&#xD;
&#xD;
          2. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the&#xD;
             prostate.&#xD;
&#xD;
          3. Ineligible or averse to chemotherapeutic treatment options.&#xD;
&#xD;
          4. Patients must have progressive mCRPC at the time of consent based on at least 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Serum/plasma PSA progression defined as increase in PSA greater than 25% and &gt;2&#xD;
                  ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks&#xD;
                  apart.&#xD;
&#xD;
               2. Soft-tissue progression defined as an increase ≥20% in the sum of the diameter&#xD;
                  (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all&#xD;
                  target lesions based on the smallest SOD since treatment started or the&#xD;
                  appearance of one or a new lesion.&#xD;
&#xD;
               3. Progression of bone disease: evaluable disease or one new bone lesion by bone&#xD;
                  scan&#xD;
&#xD;
          5. Previous treatment with one ARAT (abiraterone or enzalutamide or darolutamide or&#xD;
             apalutamide) in either the CSPC or CRPC setting.&#xD;
&#xD;
          6. PSMA-PET scan (i.e., 68Ga-PSMA-11 or 18F-DCFPyL) positive as determined by the&#xD;
             sponsor's central reader.&#xD;
&#xD;
          7. Castrate circulating testosterone levels (&lt;1.7 nmol/L or &lt;50 ng/dL).&#xD;
&#xD;
          8. Adequate organ function, independent of transfusion:&#xD;
&#xD;
             a. Bone marrow reserve: i. White blood cell (WBC) count ≥2.5 × 109/L OR absolute&#xD;
             neutrophil count (ANC) ≥1.5 × 109/L.&#xD;
&#xD;
             ii. Platelets ≥100 × 109/L. iii. Hemoglobin ≥8 mmol/L. b. Liver function: i. Total&#xD;
             bilirubin ≤1.5 × institutional upper limit of normal (ULN). For patients with known&#xD;
             Gilbert's syndrome, ≤3 × ULN is permitted.&#xD;
&#xD;
             ii. ALT or AST ≤3.0× ULN. c. Renal function: i. Serum/plasma creatinine ≤1.5 × ULN or&#xD;
             creatinine clearance ≥50 mL/min based on Cockcroft-Gault formula.&#xD;
&#xD;
             d. Albumin ≥30 g/L.&#xD;
&#xD;
          9. Human immunodeficiency virus-infected patients who are healthy and have a low risk of&#xD;
             acquired immunodeficiency syndrome-related outcomes are included in this trial.&#xD;
&#xD;
         10. For patients who have partners of childbearing potential: Partner and/or patient must&#xD;
             use a method of birth control with adequate barrier protection, deemed acceptable by&#xD;
             the principal investigator during the study and for 6 months after last study drug&#xD;
             administration.&#xD;
&#xD;
         11. Willing to initiate ARAT therapy (either enzalutamide or abiraterone), pre-specified&#xD;
             by investigator, if randomized to Treatment Arm B.&#xD;
&#xD;
         12. ECOG performance status 0 to 1.&#xD;
&#xD;
         13. Willing and able to comply with all study requirements and treatments (including 177Lu&#xD;
             PNT2002) as well as the timing and nature of required assessments.&#xD;
&#xD;
         14. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          1. Prostate cancer with known significant (&gt;10%) sarcomatoid or spindle cell or&#xD;
             neuroendocrine components. Any small cell component in the cancer should result in&#xD;
             exclusion.&#xD;
&#xD;
          2. Prior treatment for prostate cancer ≤28 days prior to randomization, with the&#xD;
             exclusion of first-line local external beam, ARAT, luteinizing hormone-releasing&#xD;
             hormone (LHRH) therapy, or non-radioactive bone-targeted agents.&#xD;
&#xD;
          3. Any prior cytotoxic chemotherapy for CRPC (e.g., cabazitaxel or docetaxel);&#xD;
             chemotherapy for hormone-sensitive prostate cancer (HSPC) is allowed if the last dose&#xD;
             was administered &gt;1 year prior to consent.&#xD;
&#xD;
          4. Prior treatment with systemic radionuclides (e.g. radium-223, rhenium-186, strontium&#xD;
             89).&#xD;
&#xD;
          5. Prior immuno-therapy, except for sipuleucel-T.&#xD;
&#xD;
          6. Prior PSMA-targeted radioligand therapy, e.g., Lu-177-PSMA-617, I 131-1095.&#xD;
&#xD;
          7. Prior poly ADP ribose polymerase (PARP) inhibitor for prostate cancer.&#xD;
&#xD;
          8. Patients who have had 2 or more lines of ARATs.&#xD;
&#xD;
          9. Patients receiving bone-targeted therapy (e.g. denosumab, zoledronic acid) must be on&#xD;
             stable doses for at least 4 weeks prior to randomization.&#xD;
&#xD;
         10. Administration of an investigational agent ≤60 days or 5 half-lives, whichever is&#xD;
             shorter, prior to randomization.&#xD;
&#xD;
         11. Major surgery ≤30 days prior to randomization.&#xD;
&#xD;
         12. Estimated life expectancy &lt;6 months as assessed by the principal investigator.&#xD;
&#xD;
         13. Presence of liver metastases &gt;1 cm on abdominal imaging.&#xD;
&#xD;
         14. A superscan on bone scan defined as a bone scan that demonstrates markedly increased&#xD;
             skeletal radioisotope uptake relative to soft tissues in association with absent or&#xD;
             faint genitourinary tract activity71.&#xD;
&#xD;
         15. Use of opioids for cancer-related pain ≤30 days prior to consent.&#xD;
&#xD;
         16. Known presence of central nervous system metastases.&#xD;
&#xD;
         17. Contraindications to the use of planned ARAT therapy.&#xD;
&#xD;
         18. Active malignancy other than low-grade non-muscle-invasive bladder cancer and non&#xD;
             melanoma skin cancer.&#xD;
&#xD;
         19. Concurrent illness that may jeopardize the patient's ability to undergo study&#xD;
             procedures.&#xD;
&#xD;
         20. Serious psychological, familial, sociological, or geographical condition that might&#xD;
             hamper compliance with the study protocol and follow-up schedule. Patients that travel&#xD;
             need to be capable of repeated visits even if they are on the control arm.&#xD;
&#xD;
         21. Symptomatic cord compression, or clinical or radiologic findings indicative of&#xD;
             impending cord compression.&#xD;
&#xD;
         22. Concurrent serious (as determined by the investigator) medical conditions, including,&#xD;
             but not limited to, New York Heart Association class III or IV congestive heart&#xD;
             failure (see 12.1 Appendix 1), unstable ischemia, uncontrolled symptomatic arrhythmia,&#xD;
             history of congenital prolonged QT syndrome, uncontrolled infection, known active&#xD;
             hepatitis B or C, or other significant co-morbid conditions that in the opinion of the&#xD;
             investigator would impair study participation or cooperation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Jensen</last_name>
    <role>Study Director</role>
    <affiliation>POINT Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Cioci</last_name>
    <phone>+1-833-544-2637</phone>
    <phone_ext>202</phone_ext>
    <email>SPLASH@pointbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Associates (CUA) P.A.</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>VA St. Louis Health Care System</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Cancer Center, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Excel Diagnostics &amp; Nuclear Oncology Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU of Quebec - Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016 Jul;57(7):1006-13. doi: 10.2967/jnumed.115.168443. Epub 2016 Jan 21.</citation>
    <PMID>26795286</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>September 19, 2021</last_update_submitted>
  <last_update_submitted_qc>September 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PSMA</keyword>
  <keyword>mCRPC</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>177Lu-PSMA</keyword>
  <keyword>radioligand therapy</keyword>
  <keyword>PSMA-I&amp;T</keyword>
  <keyword>SPLASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

